Fig. 5

Mutation Rate and patients' categorization based on the Tier classification of the most clinically significant variant for each tumor histology. The following categories were used: 1A/1B: patients harboring alterations that are biomarkers for on-label treatments or with strong evidence of predictive value for an on-label treatment (Tier 1), 2C.1: patients with biomarkers related to off-label treatment, 2C.2: patients with biomarkers related to clinical trials, 2D: patients with biomarkers with preclinical evidence of predictive value, 3: patients harboring alterations with conflicting evidence of cancer association. B. Percentage of patients with On-label and off-label mutations identified and the type of alterations detected. Genes of the homologous recombination complex are labeled in blue.